In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications.

The companyis backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures, MRL Ventures Fund, and Bioqube Ventures.